Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 10/20 | 0.58 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | ITGB3 | P05106 | 6/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14137066 | 0.92 | DGAT1 (0.65) | DGAT1HRH3ITGB3ITGA2B | |
| SCHEMBL17200568 | 0.90 | HRH3 (0.61) | DGAT1HRH3KCNH2 | |
| SCHEMBL17200607 | 0.90 | DGAT1 (0.52) | DGAT1HRH3ITGB3ITGA2BKCNH2 | |
| SCHEMBL17200581 | 0.87 | HRH3 (0.60) | DGAT1HRH3ITGB3ITGA2BEPHX2 | |
| SCHEMBL17211823 | 0.87 | DGAT1 (0.56) | DGAT1HRH3ITGB3ITGA2BKCNH2 | |
| SCHEMBL17200622 | 0.82 | DGAT1 (0.63) | DGAT1HRH3 | |
| SCHEMBL14060086 | 0.82 | DGAT1 (0.65) | DGAT1ITGB3ITGA2B | |
| SCHEMBL2182154 | 0.82 | DGAT1 (0.59) | DGAT1 | |
| SCHEMBL27942846 | 0.81 | ITGB3 (0.58) | DGAT1ITGB3ITGA2B | |
| SCHEMBL14137055 | 0.80 | DGAT1 (0.58) | DGAT1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | claimed |
| EP-2723332-B1 | NOVEL COMPOUNDS AS DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2016-03-02 | — | — | EP | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
| CN-103687595-A | Novel compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE IP NO 2 LTD | 2014-03-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | DGAT1 1/4885HRH3 4193/4885ITGB3 3896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.